Diffusion of biosimilar hemopoietic growth factors use in oncology practice: an Italian experience-Reference-Cited by-同舟云学术

Diffusion of biosimilar hemopoietic growth factors use in oncology practice: an Italian experience

Published:2015-07-18 Issue:1 Volume:17 Page:
ISSN:1590-9158
Container-title:PharmacoEconomics Italian Research Articles
language:en
Short-container-title:PharmacoEcon Ital Res Artic

Author:

Perfetti Vittorio,Dalle Carbonare Simona,Vecchio Silvia,Paglino Chiara,Secondino Simona,Tringali Michele,Pedrazzoli Paolo,Dellagiovanna Mirosa

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy

Link

http://link.springer.com/content/pdf/10.1007/s40276-015-0026-1.pdf

Reference8 articles.

1. European Medicine Agency. Comparability of biotechnological/biological products—ICH topic Q 5 E. June 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002805.pdf . Accessed on January 9, 2015.

2. European Medicine Agency. Guideline on similar biological medicinal products. CHMP/437/04 Rev 1, October 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf . Accessed on January 9, 2015.

3. Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15:223–8.

4. AIFA Position Paper sui Farmaci Biosimilari. 2013. www.agenziafarmaco.gov.it/content/position-paper or http://www.agenziafarmaco.gov.it/sites/default/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf . Accessed on January 9, 2015.

5. IMS Institute for healthcare Informatics. Assessing biosimilar uptake and competition in European markets. October 2014. http://www.imshealth.com/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Insights/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf .